Abstract
Gemcitabine and 5-fluorouracil are the only two compounds with reproducible activity against advanced pancreatic cancer (APC). We have evaluated a novel combination of gemcitabine and 5-fluorouracil on the clinical benefit response (CBR) end point. Eleven consecutive patients with symptomatic APC were entered in a two-stage phase II trial. Gemcitabine was administered by intravenous (i.v.) bolus injection at the dose of 1000 mg m–2 on days 1, 8, 15 and 5-fluorouracil 500 mg m–2 was given by continuous i.v. infusion on days 1–5. Treatment was repeated every 28 days. A CBR was achieved in 7/11 patients. The mean time to loss of CBR was 26.5 weeks (range 14–18, median 22). Toxicity was mild and no APC patient experienced WHO grade 3 toxicity. The gemcitabine/5-fluorouracil combination is well tolerated and produces a symptomatic relief in the majority of APC patients. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aaranson NK, Ahmedzai S and Bergman B (1993) The European Organization for Research and Treatment of Cancer QL C-30: a quality of life instrument for use in international clinical trials in Oncology. J Natl Cancer Inst 85: 365–376
Burris H, Moore MJ and Andersen J (1995) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with Advanced Pancreatic Cancer: a randomized trial. J Clin Oncol 15: 2403–2413
Carmichael J (1997) Clinical response benefit in patients with advanced pancreatic cancer: role of gemcitabine. Digestion 58: 503–507
Cascinu S, Frontini L and Labianca R (1997) Gemcitabine (Gem) and 5-Fluorouracil (5-FU) in advanced pancreatic cancer, a GISCAD phase II study. Proc ECCO 33: S280 (A1268)
Crown J, Casper ES and Biotet J (1991) Lack of efficacy of high dose leucovorin and 5 Fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 8: 1682–1686
Hidalgo M, Paz-Ares L and Hitt R (1997) Phase I–II study of gemcitabine combined with continuous infusion 5-fluorouracil as first-line chemotherapy in locally advanced and symptomatic pancreatic cancer. Proc Am Soc Clin Oncol 16: A1030
Noble S and Goa KL (1997) Gemcitabine: a review of its pharmacology and clinical potential in non-small-cell lung cancer and pancreatic cancer. Drugs 54: 447–472
Rubin J, Gallangher JG and Schroeder G (1996) Phase II trial of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 78: 1888–1891
Simon R (1989) Optimal two stage designs for phase II clinical trials. Control Clin Trials 10(1): 1–10
Stephens CD (1998) Gemcitabine: a new approach to treating pancreatic cancer. Oncol Nurs Forum 25: 87–93
Von Hoff DD (1996) Activity of gemcitabine in a human cloning assay as a basis for clinical trials with gemcitabine. San Antonio Development Team. Invest New Drug 14: 265–270
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Matano, E., Tagliaferri, P., Libroia, A. et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer 82, 1772–1775 (2000). https://doi.org/10.1054/bjoc.1999.1139
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1139
Keywords
This article is cited by
-
Patient-reported outcomes as end points and outcome indicators in solid tumours
Nature Reviews Clinical Oncology (2015)
-
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer
Journal of Cancer Research and Clinical Oncology (2012)
-
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
British Journal of Cancer (2005)
-
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene
Cancer Gene Therapy (2001)